Skip to content

Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for Cancer

Prehabilitaion Program for Sarcopenic Patients Prior to Pancreaticoduodenectomy for Periampullary Malignant Tumors

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04469504
Acronym
PSOAS
Enrollment
158
Registered
2020-07-14
Start date
2022-05-17
Completion date
2028-05-31
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia, Pancreatic Cancer

Keywords

morbimortality, Prehabilitaion, pancreatic surgery, cephalic duodenopancreatectomy

Brief summary

Major digestive surgery is associated with a significant rate of postoperative complications. To improve postoperative outcome, efforts are focused on postoperative course leading to the concept of rehabilitation. However, the rehabilitation concept does not allow to improve muscular and functional reserves at the time of surgery. Sarcopenia is a condition characterized by loss of skeletal muscle mass and function. Also, the prevalence of sarcopenia in patients with cancer is high and has a prevalence of around 25% in patients with pancreatic cancer, with a considerable impact on postoperative and survival outcomes. The hypothesis is the preoperative management of sarcopenia by a rehabilitation program could improve patients' operative outcomes by reducing the rate of postoperative complications.

Interventions

4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support

DIETARY_SUPPLEMENTOral Impact

perioperative immunonutrition by ORAL IMPACT

Sponsors

Groupement Interrégional de Recherche Clinique et d'Innovation
CollaboratorOTHER
Santelys Association
CollaboratorOTHER
University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing pancreaticoduodenectomy for cancer * Sarcopenic status

Exclusion criteria

* Age younger than 18 years * Medical contraindications including cardiovascular disease or clinically significant vascular disease * Physical inability to exercise * Emergent surgery

Design outcomes

Primary

MeasureTime frameDescription
Post-operative severe pancreatic fistula (Grade B and C)at 90 daysPancreatic fistula as defined by the International Study Group of pancreatic Fistula (ISGPF)

Secondary

MeasureTime frameDescription
Overall survivalat 1 year and at 3 years
Program acceptance measure by Modified ACCEPT© questionnaireat 30 days
Rate of program completionat 30 daysself questionnaire to measure opinion with respect of rehabilitation program
Rate of Severe postoperative complicationsat 90 daysGrade \> IIIa (Clavien-Dindo classification)
Satisfaction questionnaire by the questionnaire for satisfaction of hospitalized (QSH-45)at 30 daysFrench self-administered instrument for measuring hospitalized patients' satisfaction based on the patient's point of view. QSH contained 45 items describing 9 dimensions, leading to 2 composite scores (staff and structure index)
Quality of life by EORTC-QLQc30 scaleat 1 month, 3 months, 6 months and at 1 yearThe QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The questionnaire includes one global health status/QoL scale, five functional scales and three symptom scale. Each scale is scored from 0 to 100. A high score on a scale indicate a good outcome for the dimension of QoL.
Satisfaction questionnaire by EVAN-Gat 30 daysEVAN-G general patient satisfaction questionnaire consisting of 26 items divided into 6 sub-sections scoring on a scale from 0 to 100. It is designed to report perioperative problems.

Countries

France

Contacts

Primary ContactMehdi ELAMRANI, MD
mehdi.elamrani@chru-lille.fr0320444465

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026